Johnson & Johnson Reports Q4 and Full-Year 2022 Results

NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.”OVERALL FINANCIAL RESULTS Q4Full Year($ in Millions, except EPS)20222021% Change20222021%  ChangeReported Sales$23,706$24,804(4.4)%$94,943$93,7751.3%Net Earnings$3,520$4,736(25.7)%$17,941$20,878(14.1)%EPS (diluted)$1.33$1.77(24.9)%$6.73$7.81(13.8)%        Q4Full YearNon-GAAP* ($ in Millions, except EPS)20222021%  Change20222021%  ChangeOperational Sales1,2  0.9%  6.1%Adjusted Operational Sales1,3  0.8%  6.2%Adjusted Net Earnings1,4$6,218$5,6789.5%$27,038$26,1953.2%Adjusted EPS (diluted)1,4$2.35$2.1310.3%$10.15$9.803.6%  1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules  2 Excludes the impact of translational currency  3 Excludes the net impact of acquisitions and div...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news